ArticleScientific reports2025
Integrative genomics characterizes HCC eRNAs for prognosis and targeted therapy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrative multi-omics analysis reveals a membrane tension signature associated with tumor-stroma crosstalk in hepatocellular carcinoma.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC), a leading cause of cancer-related mortality globally, exhibits limited diagnostic and therapeutic biomarkers despite its clinical significance. Emerging evidence has positioned enhancer RNAs (eRNAs) as pivotal regulators in tumorigenesis, prompting this study to systematically identify HCC-specific eRNA signatures and elucidate their functional relevance. Through integrative analysis of three independent cohorts (n = 115 tumor-normal pairs), we identified three eRNA biomarkers-CAP2e, COLEC10e, and MARCOe-exhibiting significant differential expression between HCC and adjacent tissues, with validation in The Cancer Genome Atlas Liver Hepatocellular Carcinoma (TCGA-LIHC) dataset. Notably, these eRNAs demonstrated strong positive correlation with their host genes (r > 0.83, p < 0.05), suggesting co-regulatory mechanisms. Functional enrichment revealed their involvement in oncogenic pathways including MAPK signaling, with MARCOe emerging as a candidate therapeutic target due to its association with immune evasion pathways. Multi-omics characterization including survival analysis, immune infiltration profiling, and pan-cancer comparison further validated these eRNAs' diagnostic specificity and prognostic value. Critical experimental validation of MARCO was performed via immunohistochemistry (IHC) in 60 HCC tumor-normal paired samples, demonstrating significantly reduced MARCO protein expression in tumors (tumor vs. normal: 15% vs. 65% positivity, p < 0.001). MARCO overexpression experiments in HCC cells revealed significant alterations in MAPK pathway-related genes, suggesting potential therapeutic implications through pathway modulation. This investigation provides the first comprehensive identification of clinically relevant eRNA biomarkers for HCC, establishing their dual roles in disease progression and therapeutic targeting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.